Ranaveksim (Powder) Instructions for Use
Marketing Authorization Holder
Avexima JSC (Russia)
Manufactured By
Avexima Siberia LLC (Russia)
ATC Code
D06BA05 (Sulfanilamide)
Active Substance
Sulfanilamide (Rec.INN registered by WHO)
Dosage Forms
 |
Ranaveksim | Powder for external use 2 g: bottle with dispenser |
| Powder for external use 5 g: bottle with dispenser | ||
| Powder for external use 10 g: bottle with dispenser |
Dosage Form, Packaging, and Composition
Powder for external use white or almost white, crystalline.
| 1 bottle | |
| Sulfanilamide | 2 g |
Polymer bottles (1) with a dispenser – cardboard packs.
Powder for external use white or almost white, crystalline.
| 1 bottle | |
| Sulfanilamide | 5 g |
Polymer bottles (1) with a dispenser – cardboard packs.
Powder for external use white or almost white, crystalline.
| 1 bottle | |
| Sulfanilamide | 10 g |
Polymer bottles (1) with a dispenser – cardboard packs.
Clinical-Pharmacological Group
A drug with antibacterial action for external use
Pharmacotherapeutic Group
Antibiotics and antimicrobial agents used in dermatology; antimicrobial agents for topical use; sulfonamides
Pharmacological Action
Antimicrobial agent, Sulfanilamide, one of the first representatives of chemotherapeutic agents of the sulfonamide group. It has a bacteriostatic effect.
The mechanism of action is due to competitive antagonism with PABA and competitive inhibition of the enzyme dihydropteroate synthase.
This leads to a disruption in the synthesis of dihydrofolic, and then tetrahydrofolic acid, and as a result, to a disruption in the synthesis of nucleic acids.
It is active against gram-positive and gram-negative cocci, Escherichia coli, Shigella spp., Vibrio cholerae, Haemophilus influenzae, Clostridium spp., Bacillus anthracis, Corynebacterium diphtheriae, Yersinia pestis, as well as against Chlamydia spp., Actinomyces spp., Toxoplasma gondii.
Indications
As part of complex therapy: purulent wounds, infected burns (I-II degree) and other purulent-inflammatory skin processes.
ICD codes
| ICD-10 code | Indication |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply the powder externally onto the affected skin areas or onto a sterile gauze pad.
Use a thin, even layer to cover the entire wound surface.
Apply to mucous membranes with caution, ensuring the area is clean and dry.
Change the wound dressing every 1-2 days or more frequently if significant exudate is present.
Before reapplication, cleanse the wound thoroughly of any residual exudate or previous powder.
The standard course of treatment is 10-14 days.
Do not exceed the recommended treatment duration without medical supervision.
Discontinue use and consult a physician if no improvement is observed within 3-5 days.
Avoid contact with eyes and other sensitive areas.
Wash hands before and after applying the medication.
Adverse Reactions
Allergic reactions skin manifestations.
With long-term use in high doses : systemic action: headache, dizziness, nausea, vomiting, dyspepsia, cyanosis, crystalluria.
Contraindications
Severe renal failure, blood diseases, bone marrow depression, anemia, chronic heart failure, thyrotoxicosis, hepatic failure, azotemia, porphyria, glucose-6-phosphate dehydrogenase deficiency, pregnancy, lactation, hypersensitivity to sulfonamides.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Use in Hepatic Impairment
Contraindicated in renal failure.
Use in Renal Impairment
Contraindicated in severe renal failure, nephrosis, nephritis. Use with caution in patients with impaired renal function. During treatment, it is necessary to increase the volume of fluid consumed.
Pediatric Use
Use is possible according to the dosage regimen.
Special Precautions
Premature discontinuation of treatment may contribute to the development of sulfonamide-resistant strains of microorganisms.
During therapy, plenty of alkaline fluids are recommended.
If necessary, antimicrobial drugs are prescribed simultaneously orally.
If allergic reactions develop, it is necessary to discontinue the drug and prescribe appropriate treatment.
Drug Interactions
Myelotoxic drugs enhance the manifestations of hematotoxicity.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer![Ranaveksim [Powder] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Ranaveksim [Powder] 2")